Literature DB >> 25053854

Is deferred use of bevacizumab for glioblastoma associated with prolonged survival?

Quintino Giorgio D'Alessandris1, Gabriele Capo1, Roberto Pallini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25053854      PMCID： PMC4165424          DOI： 10.1093/neuonc/nou150

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  5 in total

1.  Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825.

Authors:  Michael Weller; W K Alfred Yung
Journal:  Neuro Oncol       Date:  2013-08       Impact factor: 12.300

2.  Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.

Authors:  Mohamed A Hamza; Jacob J Mandel; Charles A Conrad; Mark R Gilbert; W K Alfred Yung; Vinay K Puduvalli; John F DeGroot
Journal:  J Neurooncol       Date:  2014-05-07       Impact factor: 4.130

3.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

4.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.

Authors:  David E Piccioni; Julia Selfridge; Reema R Mody; Reshmi Chowdhury; Sichen Li; Shadi Lalezari; James Wawrzynski; Jennifer Quan; Mira Zurayk; Arthur P Chou; Desiree E Sanchez; Linda M Liau; Benjamin M Ellingson; Whitney B Pope; Phioanh L Nghiemphu; Richard M Green; He-Jing Wang; William H Yong; Robert Elashoff; Timothy F Cloughesy; Albert Lai
Journal:  Neuro Oncol       Date:  2014-03-13       Impact factor: 12.300
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.